Formulary
Vancomycin: Uses, Dosing, Side Effects and Indian Brand Names
Vancomycin is a glycopeptide antibiotic targeting D-Ala-D-Ala in peptidoglycan synthesis, the drug of choice for serious MRSA infections (IV) and C. difficile colitis (oral), requiring therapeutic drug monitoring.
MedNext Academy | 5 min read
Clinically reviewed by Awaiting clinical review
Vancomycin: Uses, Dosing, Side Effects and Indian Brand Names
Vancomycin is a glycopeptide antibiotic targeting D-Ala-D-Ala in peptidoglycan synthesis, the drug of choice for serious MRSA infections (IV) and C. difficile colitis (oral), requiring therapeutic drug monitoring.
NEET PG High-Yield: Binds D-Ala-D-Ala in peptidoglycan. Acts at a step BEFORE PBPs (outside the cell membrane). Does NOT penetrate Gram-negative outer membrane. Red Man Syndrome: NOT an allergy (histamine, not IgE); prevent by slow infusion. VRE resistance mechanism: D-Ala-D-Lac substitution (1000x reduced binding). Oral vancomycin: NOT absorbed -- used for C. difficile only. AUC/MIC-guided dosing. Nephrotoxicity + ototoxicity. Drug of choice for MRSA. Synergistic with aminoglycosides against enterococci.
Clinical overview
Vancomycin is the glycopeptide antibiotic that serves as the last-resort drug for serious methicillin-resistant Staphylococcus aureus (MRSA) infections and the cornerstone of treatment for Clostridioides difficile colitis (oral vancomycin). Its mechanism of binding to D-Ala-D-Ala is elegant and historically effective, though vancomycin-resistant enterococci (VRE) have emerged by substituting D-alanyl-D-lactate (D-Ala-D-Lac) at the terminal position, which reduces vancomycin binding affinity by 1000-fold. Vancomycin-resistant S. aureus (VRSA) remains rare globally but has been reported. IV vancomycin requires therapeutic drug monitoring (TDM) targeting an AUC/MIC ratio of 400-600 (current guidelines favour AUC-guided dosing over trough-only monitoring). Two critical toxicities must be understood: nephrotoxicity (dose-dependent, potentiated by aminoglycosides) and Red Man Syndrome (RMS) -- a histamine-mediated pseudoallergic reaction causing flushing, erythema, and pruritus of the upper body, caused by rapid infusion. RMS is NOT a true allergy and is prevented by slowing the infusion rate to at least 1 hour (or longer for doses >1 g). Ototoxicity is less common and usually associated with supratherapeutic levels or concurrent ototoxic drugs. Oral vancomycin is NOT absorbed from the GI tract, which is why it is specifically used for C. difficile colitis (where it acts locally in the colon) but is useless orally for systemic infections.
Pharmacological class
Vancomycin belongs to the Glycopeptide Antibiotics class. Binds to the D-alanyl-D-alanine (D-Ala-D-Ala) terminus of peptidoglycan precursors (lipid II) on the outer surface of the cytoplasmic membrane, preventing transglycosylation and transpeptidation. This blocks cell wall synthesis at a step BEFORE the penicillin-binding protein target. Vancomycin is bactericidal against most organisms (slowly) and exhibits time-dependent killing. It cannot penetrate the outer membrane of Gram-negative bacteria, limiting its spectrum to Gram-positives.
Indian brand names and formulations
Available as: Vancocin (Eli Lilly/Flynn), Vancoplus (Aristo), Vancogen (Glenmark), Vancomycin IP (various generic).
IV powder for reconstitution: 500 mg, 1 g vials. Oral capsules: 125 mg, 250 mg (for C. difficile -- IV formulation can also be given orally at lower cost). IV solution can be given orally for CDI as a cost-saving measure in India.
Regulatory status
Vancomycin is classified under Schedule H in India under the Drugs and Cosmetics Act, 1940. Prescription-only. Reserve antibiotic -- should be used only when indicated, per antimicrobial stewardship. IV formulation is expensive; oral capsules are also costly.
Indications
- MRSA infections: bacteraemia, endocarditis, osteomyelitis, pneumonia, meningitis
- Clostridioides difficile infection (oral vancomycin -- first-line for moderate-to-severe CDI)
- Serious Gram-positive infections in penicillin-allergic patients (e.g., Enterococcus endocarditis)
- Prosthetic valve endocarditis (with rifampicin and gentamicin)
- CNS shunt infections (intrathecal/intraventricular)
- Empiric therapy for febrile neutropenia with suspected line-related Gram-positive infection
Dosing
IV: 15-20 mg/kg (actual body weight) every 8-12 hours. Loading dose: 25-30 mg/kg for critically ill patients. Target: AUC/MIC 400-600 (AUC-guided dosing preferred over trough-only). Infusion rate: over at least 1 hour (max 10 mg/min) to prevent Red Man Syndrome. Oral (for C. difficile): 125 mg four times daily for 10 days. Renal impairment: reduce frequency based on CrCl and TDM. Haemodialysis: redose guided by trough levels (vancomycin is poorly dialysed).
Contraindications
- Known hypersensitivity to vancomycin (true anaphylaxis, not Red Man Syndrome)
- Note: Red Man Syndrome is NOT a contraindication -- it is prevented by slow infusion
Adverse effects
- Red Man Syndrome (histamine-mediated flushing, erythema, pruritus of upper body and face; NOT an allergy; caused by rapid infusion; prevented by slowing infusion to >1 hour and premedication with antihistamines)
- Nephrotoxicity (dose-dependent; risk increased with concurrent aminoglycosides, NSAIDs, and in dehydrated patients)
- Ototoxicity (tinnitus, hearing loss -- usually at supratherapeutic levels or with concurrent ototoxic drugs)
- Thrombophlebitis at infusion site
- Neutropenia (with prolonged use >2 weeks)
Drug interactions
- Aminoglycosides (gentamicin, amikacin): synergistic against enterococci but ADDITIVE nephrotoxicity and ototoxicity; monitor renal function and drug levels closely
- Loop diuretics (furosemide): additive ototoxicity
- Anaesthetic agents: concurrent use during induction may cause hypotension and erythema (histamine release)
- NSAIDs: additive nephrotoxicity risk
Pregnancy and lactation
Category C (previously B in some references). Limited data in pregnancy. Used when clearly needed for serious infections (e.g., MRSA bacteraemia in pregnancy). Potential for foetal ototoxicity at high doses -- monitor maternal drug levels closely.
Exam-style clinical scenario
A patient on IV vancomycin develops diffuse flushing and erythema of the face, neck, and upper torso during the first infusion. BP is 110/70 and there is no airway compromise. Is this anaphylaxis? No -- this is Red Man Syndrome (histamine release from mast cells due to rapid infusion). Stop the infusion, give diphenhydramine 50 mg IV, wait 30 minutes, then restart at a slower rate (over 2 hours).
Cost in India
Rs 200-500 per 500 mg vial (IV). Oral capsules: Rs 100-200 per capsule (125 mg). One of the more expensive commonly used antibiotics in India.
Clinical governance
Author: MedNext Editorial Team. Clinical reviewer: Awaiting clinical review. Jurisdiction: India (Drugs and Cosmetics Act, 1940). Sources: CIMS India, Indian Pharmacopoeia. Publication state: Awaiting clinical review. Correction: Report errors at support@mednext.academy.
Frequently Asked Questions
Why is oral vancomycin not absorbed but still effective for C. difficile?
Oral vancomycin is a large glycopeptide molecule (MW ~1449 Da) that is not absorbed from the GI tract. This is actually advantageous for C. difficile colitis because the drug stays in the intestinal lumen at very high concentrations, directly killing C. difficile in the colon where the infection resides. For systemic infections (bacteraemia, endocarditis, osteomyelitis), IV vancomycin is essential because the oral route produces zero serum levels.
How does VRE resistance work?
Vancomycin-resistant enterococci (VRE, primarily E. faecium) carry van gene clusters (most commonly vanA or vanB). The vanA operon encodes enzymes that substitute D-lactate for the terminal D-alanine in peptidoglycan precursors (D-Ala-D-Lac instead of D-Ala-D-Ala). This single substitution reduces vancomycin's binding affinity by approximately 1000-fold because the critical hydrogen bond between vancomycin and D-Ala is replaced by an ester oxygen that creates steric repulsion.
When should vancomycin trough levels be checked?
Current guidelines recommend AUC-guided dosing (target AUC/MIC 400-600) rather than trough-only monitoring for serious MRSA infections. If trough monitoring is used (which remains common in many Indian hospitals), target troughs of 15-20 mcg/mL for serious infections. Draw trough level immediately BEFORE the 4th dose (steady state). Check creatinine concurrently. Recheck levels if renal function changes.
Inside MedNext for this topic
- 411 MedNext-authored chapters
- 80,000+ MCQ bank
- 15 study modes
- Growing visual cheat sheets
Study modes
- Notes
- MCQ
- Audio
- Video
- Visual
- 3D Anatomy
- Trace
- Flashcards
- Mnemonics
- Image Bank
- Clinical
- Microscopy
- Audio QBank
- Cadaver
- Book Match
Continue reading
Subject HubPharmacology Hub
All pharmacology resources in one place.
Drug SchedulesIndian Drug Schedules
Schedule H, H1, X and G classifications.
Test yourself on Vancomycin
Challenge yourself with targeted pharmacology MCQs on this drug class. Every explanation links back to the chapter that teaches the concept.
Start drug challengeExplore the full formulary